The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12625001073493p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
17/06/2025
Date registered
Help: Date registered
2/10/2025
Date last updated
Help: Date last updated
2/10/2025
Date data sharing statement initially provided
Help: Data sharing statement date
2/10/2025
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
efficacy of TrAnsauricular Vagal Nerve Stimulation to reduce postoperative delirium severity: a double-blind randomised, sham-controlled feasibility study (TAVerNS)
Scientific title
efficacy of TrAnsauricular Vagal Nerve Stimulation to reduce postoperative delirium severity in surgical patients aged 60 years and older: a double-blind randomised, sham-controlled feasibility study (TAVerNS)
Additional trial identifiers [1] 314664 0
TAVerNS
Universal Trial Number (UTN)
Trial acronym
TAVerNS
Related trial records

Health condition
Health condition(s) studied:
Delirium 337845 0
Condition category
Condition code
Neurological 334176 334176 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Stimulation or Sham using a PROFILE TENS Machine
Stimulation protocol: Stimulation on day of surgery (after incision closure) will be through the tragus using a standard taVNS machine. Stimulation will be delivered for 30 minutes (pulse width: 200 µs, frequency: 30 Hz) for each stimulation session (POD1 and 2 prior to assessments. Stimulation will be initiated at 10 mA, and turned down 2mA every 20 seconds until participants no longer feel it. This final value will be recorded. Bilateral taVNS was chosen because there may be improved neural plasticity responses and proven perioperative safety.
Sham protocol: For the sham group, the same stimulation protocol will be followed, however electrodes will be connected to the earlobes to prevent vagus nerve stimulation. These will be turned off once the noticeable threshold is reached.
This will be conducted by a member of the research team and hospital scientist (PhD). Case report files will collect start and end time of stimulation or sham and instance of needing to cease due to side effects.
Intervention code [1] 331291 0
Prevention
Description of the comparator or control
Sham protocol: For the sham group, the same stimulation protocol will be followed, however electrodes will be connected to the earlobes to prevent vagus nerve stimulation. These will be turned off once the noticeable threshold is reached.
Control group
Placebo

Outcomes
Primary outcome [1] 341834 0
To test acceptability of transauricular vagal nerve stimulation (taVNS)
Timepoint [1] 341834 0
Postoperative day 3
Primary outcome [2] 341835 0
To test feasibility of recruitment to taVNS
Timepoint [2] 341835 0
At conclusion of study
Primary outcome [3] 341836 0
To test feasibility of collecting trial outcome data
Timepoint [3] 341836 0
Day of Surgery and post operative day 1
Secondary outcome [1] 448793 0
To determine the effects of taVNS on delirium severity with DRS-98
Timepoint [1] 448793 0
Postoperative day 3
Secondary outcome [2] 448794 0
To determine the effects of taVNS on EEG slow wave activity
Timepoint [2] 448794 0
Day of surgery and post operative day 1

Eligibility
Key inclusion criteria
1) Patients aged 60 years and over, 2) able to provide informed consent before surgery, 3) English speaking (for cognitive testing), 4) undergoing major non-cardiac, non-intracranial surgery (defined as a minimum anticipated stay of >2 days.
Minimum age
60 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1) Preexisting delirium or dementia, 2) cardiac arrythmia requiring therapy, 3) auricular dermatitis, 4) life expectancy <30 days.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Randomisation module in REDCap, Randomisers will administer the stimulation or sham to protocol but will not assess patient outcomes.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation created using REDCap software.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Sample size calculation: no power analysis was conducted, our first step is to pilot the technology to ensure patients will take part in the trial

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 28077 0
Royal Prince Alfred Hospital - Camperdown
Recruitment postcode(s) [1] 44281 0
2050 - Camperdown

Funding & Sponsors
Funding source category [1] 319227 0
Hospital
Name [1] 319227 0
Royal Prince Alfred Hospital- Department of Anaesthetics
Country [1] 319227 0
Australia
Primary sponsor type
Government body
Name
Sydney Local Health District
Address
Country
Australia
Secondary sponsor category [1] 321697 0
None
Name [1] 321697 0
Address [1] 321697 0
Country [1] 321697 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 317806 0
Sydney Local Health District Ethics Review Committee (RPAH Zone)
Ethics committee address [1] 317806 0
Ethics committee country [1] 317806 0
Australia
Date submitted for ethics approval [1] 317806 0
24/06/2025
Approval date [1] 317806 0
Ethics approval number [1] 317806 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 142218 0
Prof Robert Sanders
Address 142218 0
Royal Prince Alfred Hospital, Department of Anaesthetics BLDG 89, Level 4 Missenden Road Camperdown NSW 2050
Country 142218 0
Australia
Phone 142218 0
+61 0295158705
Fax 142218 0
Email 142218 0
Contact person for public queries
Name 142219 0
Kaitlin Kramer
Address 142219 0
Royal Prince Alfred Hospital, Department of Anaesthetics BLDG 89, Level 4 Missenden Road Camperdown NSW 2050
Country 142219 0
Australia
Phone 142219 0
+61 0410114737
Fax 142219 0
Email 142219 0
Contact person for scientific queries
Name 142220 0
Robert Sanders
Address 142220 0
Royal Prince Alfred Hospital, Department of Anaesthetics BLDG 89, Level 4 Missenden Road Camperdown NSW 2050
Country 142220 0
Australia
Phone 142220 0
+61 0295158705
Fax 142220 0
Email 142220 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.